The effect of vitamin D on chronic obstructive pulmonary disease

A randomized clinical trial to compare the effect of vitamin D and placebo on FEV1 in patients with chronic obstructive pulmonary disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201610306312N3

Enrollment

Registered

2017-04-01

Start date

2016-11-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease, unspecified. Chronic obstructive pulmonary disease, unspecified

Interventions

Intervention 1: Intervention group: patients in this group will receive one oral 50000 IU pearl vitamin D3, weekly for 10 weeks. Intervention 2: Control group: patients in this group will receive one

Treatment - Drugs

Intervention group: patients in this group will receive one oral 50000 IU pearl vitamin D3, weekly for 10 weeks.

Control group: patients in this group will receive one oral pearl, weekly for 10 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Eighty cases of stable COPD with vitamin D deficiency. Exclusion criteria: past history of TB; asthma; active cancer; diabetes; hypertension; ischemic heart disease; chronic kidney disease; liver failure; history of upper or lower respiratory tract infections; use of oral steroid within 1 month prior to study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
FEV1. Timepoint: Beginning of study, 3 months later. Method of measurement: Pulmonary function test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Anushiravani

International Branch, Shiraz University of Medical Sciences

amiranush23@yahoo.com+98 917 316 0616

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026